NeoGenomics Inc. revised consolidated earnings guidance for the fourth quarter of fiscal 2014. The company announced that it was raising its previously issued revenue and earnings per share guidance for the fourth quarter of 2014. The company now expects revenue of approximately $25 million and earnings per share of approximately $0.01 - $0.02 for the fourth quarter.

Previously, the company had issued revenue guidance of $23.0 million to $24.5 million and earnings per share guidance of $0.00 to $0.01 per share. On a consolidated basis, including the results of the company's newly acquired PathLogic business, it is expecting approximately 36% year over year revenue growth in the fourth quarter. Approximately 23% of this growth is coming from the company's core NeoGenomics business and the remainder from PathLogic.